E58 Monoclonal Antibody Allergen Binding Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for allergic reactions to pollen, such as immunotherapy, are limited by the risk of anaphylaxis, reduced immunogenicity from chemical modifications, and high costs associated with genetic modifications, and there is a need for effective therapeutic agents that can prevent allergic reactions without these drawbacks.

Innovation Solution

Development of a monoclonal antibody, E58, that alters the structure of Group I pollen allergens, specifically Jun a1, to prevent interaction with IgE antibodies, thereby reducing allergic reactions, and its use in immunologic compositions for therapeutic administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunotherapy is used to treat allergic reactions, then long-term protection is achieved, but the risk of anaphylaxis increases

Engineering Contradiction:

Improvelong-term protectionVSAvoidrisk of anaphylaxis

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an Fc fragment as an intermediary substance that binds to IgE antibodies, preventing them from interacting with allergens. This mediator approach allows for long-term protection by reducing free IgE levels without requiring direct allergen exposure, thereby eliminating the anaphylaxis risk associated with traditional immunotherapy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention extracts and utilizes only the Fc portion of IgG antibodies, separating this protective component from the complete antibody structure. This extracted Fc fragment can neutralize IgE without containing the allergen-binding regions that cause anaphylaxis, achieving protection while removing harmful elements

Inventive Principle:

Principle #2Taking out (Extraction)

2Object-affected harmful factors

If chemical modifications are applied to reduce IgE binding, then allergic reactions are reduced, but immunogenicity is reduced

Engineering Contradiction:

Improveallergic reactionsVSAvoidimmunogenicity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The Fc fragment serves as a mediator that indirectly reduces allergic reactions by binding and neutralizing IgE antibodies, rather than directly modifying the allergen. This approach reduces harmful effects without compromising the immunogenicity of the original allergen structure

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If genetic modifications are used to create hypoallergenic allergens, then allergic reactions are reduced, but manufacturing costs increase

Engineering Contradiction:

Improveallergic reactionsVSAvoidmanufacturing costs

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent employs Fc fragments, which can be produced through relatively simple recombinant expression systems compared to genetically modified allergens. This approach uses a cost-effective, disposable neutralizing agent rather than requiring expensive genetic engineering and validation of modified allergen proteins

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

4Measurement precision

If IgE concentration near mucosal surface increases, then allergic sensitivity increases, but susceptibility to allergic reactions increases

Engineering Contradiction:

Improveallergic sensitivityVSAvoidsusceptibility to allergic reactions

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The invention converts the harmful presence of IgE antibodies into a beneficial diagnostic marker. By measuring IgE levels and treating with Fc fragments to reduce them, the system transforms high IgE concentration from a purely harmful state into one that can be quantified and subsequently corrected, turning the sensitivity measurement into a target for therapeutic intervention

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The E58 monoclonal antibody effectively inhibits the binding of IgE antibodies to pollen allergens, reducing allergic reactions and potentially reducing the number of immunotherapy injections required, while minimizing risks associated with anaphylaxis and costs.

Implementation Method 1

a monoclonal antibody or an antigen-binding fragment thereof directed against a Group I pollen allergen

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

alters the structure of the allergen in such a way that it reduces or prevents its capacity to interact with previously formed, IgE antibody to the allergen

Methodology Applied

Scientific EffectProtein conformational change:

Data Source

PatentUS8883154B2Antibody-mediated modulation of allergy

Publication Date: 2014.11.11 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.